fWe’re not sure who coined the phrase diabesity, but it appropriately describes what Lilly and Novo Nordisk have become. These two legacy companies are no longer in the business of diabetes alone and are now as equally focused on obesity therefore they are diabesity companies. Yes, as we noted in a previous post not that long ago the fight against fat is fattening the bottom lines of Novo and Lilly.
Look at these numbers for the GLP-1 category
“For Q2 2022, worldwide Trulicity revenue was $1.91 billion, an increase of 25% compared with Q2 2021. U.S . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.